Thermo Fisher Scientific agreed to acquire data‑solutions company Clario for $8.9 billion in cash plus an additional $125 million contingent payment—bringing the deal to about $9.0–$9.4 billion depending on terms—aiming to marry Thermo Fisher’s lab and manufacturing footprint with Clario’s clinical‑trial data and software capabilities. The transaction expands Thermo Fisher’s services into trial operations and eClinical offerings at scale, supporting end‑to‑end lab‑to‑clinic workflows. The deal underscores consolidation in the trials‑technology sector as pharma seeks tighter control over data and trial logistics.